# Inhibrx Biosciences, Inc. (INBX)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $1.44B  
**Price:** $92.94 (+3.88%)

> Inhibrx Inc. is a biotechnology company that focuses on developing monoclonal antibodies used for treating a range of life-threatening diseases. The company’s primary objective is to innovate targeted therapies that can address significant unmet medical needs in the areas of oncology, rare diseases, and autoimmune conditions. Notably, Inhibrx leverages its proprietary single-domain antibody technology platform to engineer highly differentiated biological therapies. By concentrating on precision medicine, the firm's approach aims to deliver more effective solutions with the potential for enhanced patient outcomes as compared to traditional treatments. Operating in the burgeoning biotechnology sector, Inhibrx contributes to the advancement of medical research and the development of targeted therapies. The company's role in the financial market encompasses that of a high-growth potential entity, attracting interest from investors focused on cutting-edge healthcare innovations and the broader biotechnology industry developments.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1M | — | -$135M | -$140M | — |
| 2024 | $200,000 | — | -$331M | $1.69B | — |
| 2023 | $2M | — | -$219M | -$241M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $146M | $138M | $8M | $124M | $101M |
| 2024 | $181M | $47M | $134M | $153M | — |
| 2023 | $308M | $264M | $44M | $278M | $207M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$130M | $31,000 | -$130M |
| 2024 | -$194M | $3M | -$197M |
| 2023 | -$193M | $5M | -$198M |

Source: [CompaniesByCap](https://companiesbycap.com/company/INBX)